Neurocrine Biosciences Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Neurocrine Biosciences (NBIX) Tops Q1 EPS by 28c, Revenues Beat
May 6, 2020 6:12 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.82, $0.28 better than the analyst estimate of $0.54. Revenue for the quarter came in at $237.1 million versus the consensus estimate of $223.87 million.
"First and foremost, I would like to thank our employees, healthcare providers and suppliers for their commitment and dedication in managing these tough... More
